益方生物(688382) - 2023 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2023 was not applicable as all products are still in the research and development stage[8]. - Net loss attributable to shareholders for Q1 2023 was ¥117,870,350.59, with a net profit excluding non-recurring items of ¥119,811,770.67[5]. - Basic and diluted earnings per share for Q1 2023 were both -¥0.20[6]. - The weighted average return on equity for Q1 2023 was -5.24%[6]. - Total operating costs for Q1 2023 were CNY 119,810,412.20, a slight decrease of 0.14% compared to CNY 119,984,869.48 in Q1 2022[17]. - Net loss for Q1 2023 was CNY 117,870,350.59, an improvement of 1.68% from a net loss of CNY 119,878,249.53 in Q1 2022[19]. - Other comprehensive income for Q1 2023 was CNY 419,135.55, compared to a loss of CNY 136,957.90 in Q1 2022[20]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.20, an improvement from CNY -0.26 in Q1 2022[20]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,245,806,646.19, a decrease of 4.09% from the end of the previous year[6]. - As of March 31, 2023, the total current assets amounted to RMB 2,171,277,840.55, a decrease from RMB 2,265,470,912.30 as of December 31, 2022, reflecting a decline of approximately 4.2%[15]. - The total assets as of March 31, 2023, were RMB 2,245,806,646.19, down from RMB 2,341,609,014.39, marking a decrease of about 4.1%[16]. - The non-current assets totaled RMB 74,528,805.64, a decrease from RMB 76,138,102.09, reflecting a decline of approximately 2.1%[15]. - The total liabilities increased to RMB 133,131,287.51 from RMB 126,686,902.60, indicating a rise of approximately 5.4%[16]. - The company's retained earnings showed a negative balance of RMB -2,138,616,910.69, worsening from RMB -2,020,746,560.10[16]. - The total equity attributable to shareholders decreased to RMB 2,112,675,358.68 from RMB 2,214,922,111.79, a decline of about 4.6%[16]. Cash Flow - The company reported a net cash flow from operating activities of -¥81,674,325.83 for Q1 2023[5]. - Net cash flow from operating activities for Q1 2023 was CNY -81,674,325.83, compared to CNY -99,873,889.37 in Q1 2022, indicating a reduced cash outflow[21]. - Cash and cash equivalents decreased to RMB 1,645,819,421.57 from RMB 2,235,210,918.84, representing a significant drop of about 26.4%[14]. - Cash and cash equivalents at the end of Q1 2023 were CNY 1,645,819,421.57, up from CNY 615,149,649.24 at the end of Q1 2022[22]. - Investment activities resulted in a net cash outflow of CNY 501,958,351.88 in Q1 2023, compared to CNY -2,109,829.64 in Q1 2022[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,680[10]. - The largest shareholder, InventisBio Hong Kong Limited, held 19.19% of the shares, totaling 110,329,937 shares[11]. Research and Development - Research and development expenses for Q1 2023 totaled ¥110,164,964.97, representing 2.31% of total revenue[6]. - The company incurred research and development expenses of CNY 110,164,964.97 in Q1 2023, slightly up from CNY 107,678,795.28 in Q1 2022[17].